Drugs / VRC-FLUMOS0122-00-VP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07111078 | Aug 2025 → Aug 2027 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-FLUMOS0122-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07111078 ↗ |
| Known as | SteMos1 | “The VRC-FLUMOS0122-00-VP (SteMos1) is composed of de novo engineered pentamer assembled with de novo engineered trimeric domains to an icosahedral core, projecting 20 HA...” NCT07111078 ↗ |
| Modality | Vaccine | “the stem quadrivalent influenza vaccine VRC-FLUMOS0122-00-VP (SteMos1)” NCT07111078 ↗ |
| Route | Intramuscular | “The vaccine is given as an injection into the muscle of the upper arm.” NCT07111078 ↗ |